A phase II trial of imatinib (IM) in relapsed, nonresectable chondrosarcoma (CS) expressing platelet-derived growth factor receptor-α or -β (PDGFR-α/PDGFR-β): An Italian Sarcoma Group study

Authors :: Silvia Stacchiotti
Silvia Ferrari
Paolo G. Casali
Giovanni Grignani
Massimo Aglietta
Virginia Ferraresi
Sergio Frustaci
Alessandro Comandone
Antonella Boglione
Emanuela Palmerini
Source :: Journal of Clinical Oncology. 28:10060-10060
Publication Year :: 2010
Publisher :: American Society of Clinical Oncology (ASCO), 2010.
Abstract: 10060 Background: CS is a rare and heterogeneous disease in which, after failure of surgery and radiotherapy, chemotherapy has a marginal role, if any. Different molecular pathways were shown to be...

Tools